Results 231 to 240 of about 1,759,507 (251)

Latency-reversing agents: where are we now? [PDF]

open access: possibleCurrent Opinion in HIV and AIDS
Purpose of review Despite effective antiretroviral therapy (ART), HIV-1 persists in latently infected cells that evade host immunity and can resume viral production upon treatment interruption. To address this challenge, the “shock and kill” strategy aims to use latency-reversing agents (LRAs) to reactivate HIV ...
Bendoumou, Maryam, Van Lint, Carine
openaire   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

HIV latency reversal agents: A potential path for functional cure?

European Journal of Medicinal Chemistry, 2021
Despite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the 'kick-and-kill' approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4+ T ...
Juliana Romano Lopes   +2 more
openaire   +2 more sources

HIV Tat as a latency reversing agent: turning the tables on viral persistence

open access: yesFrontiers in Immunology
The ‘shock and kill’ approach to an HIV cure involves the use of latency reversing agents (LRAs) to reactivate latent HIV, with the aim to induce death of infected cells through virus induced cytolysis or immune mediated clearance. Most LRAs tested to date have been unable to overcome the blocks to transcription elongation and splicing that persist in ...
Sharon R. Lewin, Paula Cevaal
exaly   +4 more sources

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Journal of Visualized Experiments, 2019
HIV remains incurable due to the existence of a reservoir of cells that harbors stable and latent form of the virus, which stays invisible to the immune system and is not targeted by the current antiretroviral therapy (cART). Transcription and splicing have been shown to reinforce HIV-1 latency in resting CD4+ T cells. Reversal of latency by the use of
Georges, Khoury, Damian F J, Purcell
openaire   +2 more sources

Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents

Expert Opinion on Drug Discovery
HIV-infected cells may rebound due to the existence of the silent HIV-infected memory CD4+ T cells (HIV latency). This HIV latency makes the disease almost incurable. In latency, the integrated proviral DNA of HIV is transcriptionally silenced partly due to the activity of histone deacetylases (HDACs).
Shovanlal Gayen   +2 more
exaly   +3 more sources

Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents

ACS Infectious Diseases
Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol (DAG)-lactone derivative 3, with high HIV-1 latency-reversing activity, based on YSE028 (2) as a lead compound and found that the ...
Takahiro Ishii   +12 more
openaire   +2 more sources

Creation of an Improved HIV Latency Model to Test Latency Reversal Agents

HIV is a retrovirus that infects CD4+ T-cells by integrating into the human genome. During productive infection, the virus enters a latent state in a small subset of cells. This allows HIV to persist and remain undetected by the immune system and current antiretroviral therapies (ART). While ART is highly effective at controlling HIV, it is not a
openaire   +1 more source

Human Immunodeficiency Virus and Latency Reversing Agents A Path to Cure?

2017
Background: Human immunodeficiency virus (HIV), as its namesake implies, is a virus that ultimately causes a deficient immune system that can lead to Acquired Immune Deficiency Syndrome (AIDS). Since the discovery of this cytopathic virus in 1983, there have been many scientific advances in regards to its identification and treatment.
openaire   +1 more source

Home - About - Disclaimer - Privacy